Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.32 |
| ▸ | CA3 | P07451 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26552915 | 0.82 | — | — | |
| SCHEMBL291781 | 0.81 | CA2 (0.46) | CA12CA1CA2CA14DNM1 | |
| SCHEMBL291433 | 0.79 | DNM1 (0.48) | CA12CA1CA2CA14DNM1 | |
| SCHEMBL8646114 | 0.79 | DNM1 (0.48) | CA12CA1CA2CA14DNM1 | |
| SCHEMBL2887901 | 0.79 | DNM1 (0.48) | CA12CA1CA2CA14DNM1 | |
| SCHEMBL8944291 | 0.79 | DNM1 (0.48) | CA12CA1CA2CA14DNM1 | |
| SCHEMBL293641 | 0.78 | CA2 (0.48) | CA12CA1CA2CA14TDP1 | |
| SCHEMBL2853054 | 0.76 | CA2 (0.36) | CA12CA1CA2CA14 | |
| SCHEMBL10319555 | 0.75 | — | — | |
| SCHEMBL12466002 | 0.73 | CHRM2 (0.39) | CHRM2TDP1APPLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310396-B1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-06 | — | — | EP | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-8921355-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN R & D IRELAND (IE) | 2014-12-30 | — | — | US | disclosed |
| US-20140107101-A1 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors | JANSSEN R&D IRELAND (IL) | 2014-04-17 | — | — | US | disclosed |
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105473-A1 | MACROCYCLIC INDOLE DERIVATIVES USEFUL AS HEPATITIS C VIRUS INHIBITORS | IDO1, HCCS, CCNI | CHRM2 432/4885CA12 4551/4885CA1 4180/4885 |
| US-20140107101-A1 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors | IDO1, HCCS, CCNI | CHRM2 432/4885CA12 4551/4885CA1 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.